AzTrials
AzTrials

Myofascial Pelvic PainNCT07181447

NIRS for the Diagnosis of Myofascial Pelvic Pain

An observational study of Myofascial Pelvic Pain, run by University of California, Los Angeles at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Myofascial Pelvic Pain
What is being tested?
Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy
How many people
110 participants
Where
1 siteUnited States
Study dates
23 Jan 2025to 1 Sep 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The control subjects (cohort 1) will be adult 18 (>18 years of age) who lack pelvic pain or other genitourinary symptoms. The MPP cohort (cohort 2) will consist of adult women >18 years of age with pelvic floor muscle pain or tender points.

Who may be able to join

  • Women between 18 and 100 years of age
  • Pelvic pain for more than 6 months duration
  • Report an average daily pain intensity score of at least 4 (on a 0 to 10 scale)
  • Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam
  • Willing to refrain from new clinical treatments that may affect pain during the study period

Who cannot join

  • Inability to participate in clinic visits
  • Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®)
  • Active UTI or vaginal infection
  • Pregnancy, childbirth during the previous 12 months, currently planning pregnancy
  • Illicit Drug addiction/regular use of controlled substances
  • Malignancy or other serious medical condition (e.g., poorly controlled diabetes [HgA1c > 8], neurologic or rheumatic disease)
Show all 11Show fewer
  • Diagnosed with an alternate cause of pelvic pain (e.g., interstitial cystitis, vestibulodynia, vulvar dermatoses dysmenorrhea)
  • Urinary retention
  • Greater than stage 3 pelvic organ prolapse
  • Indwelling vaginal devices (e.g., pessary, contraceptive ring)
  • Inability to sign an informed consent, fill out questionnaires, or complete study interviews

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UCLA Center for Women's Pelvic Health

    Los Angeles, California, 90095

Other trials in United States

About this study

Official title: Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain

Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. There are no quantitative measures that adequately guide the physician and accurate diagnosis typically requires an internal examination by a tertiary specialist.

This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle.

Read more

We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings.

The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations by providing an inexpensive, reliable and easily available method for a variety of providers to address MPP.

Read the detailed description

DETAILED DESCRIPTION Introduction. Myofascial pelvic pain (MPP) is the predominant underlying cause in 60-90% of women with chronic pelvic pain. MPP can be debilitating, and is often associated with bladder, bowel, and sexual dysfunction. MPP can be debilitating, leading to social withdrawal, loss of productivity, impaired relationships, and psychological comorbidities. Despite the high prevalence, myofascial pain is often overlooked by first-line healthcare providers; most providers, including gynecologic and urologic specialists, lack the knowledge or experience to even identify MPP. Unfortunately, there are currently no widely accepted measures to quantify muscular fitness or dynamic function of the pelvic floor. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to differentiate between forms of myofascial dysfunction and correlate those patterns with different symptoms. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to facilitate improvements in the recognition and diagnosis of MPP.

Objective: This trial will use optical technology (near infrared spectroscopy) to provide novel imaging and physiologic measures relevant to the PFM for the diagnostic evaluation of MPP.

Primary Purpose: Diagnostics Subject Recruitment: Healthy controls, who must lack pelvic pain, bowel disturbances, urinary symptoms, or sexual dysfunction, will be recruited from the community through online and targeted advertisements in gynecology and primary clinics. IRB approval for these studies is already in place, and we have already begun recruitment of control volunteers. Subjects with MPP, defined by pelvic floor myofascial pain in the absence of other identifiable pain generators, will be recruited from the UCLA Center for Women's Pelvic Health.24 MPP subjects meeting inclusion/exclusion criteria will be approached for enrollment prior to treatment assignment. Baseline demographics and clinical data, including age, height, weight, comorbidities, past surgeries, and medications, including hormones, will be self-reported at enrollment through a questionnaire on REDCap.

Vaginal NIRS-based Pelvic Floor Assessment: An 8-channel, multipoint vaginal NIRS interface miniaturized into a tampon-sized instrument, capable of measuring regional changes in pelvic floor muscle oxygenation in different quadrants and muscle depths, will assess oxygenation and hemodynamic parameters in the pelvic floor muscles. The NIRS sensor, housed in a sterile, single use, disposable child size speculum and placed within a sterile cover, will be inserted in the vagina. The participant will then complete two rounds of the same standardized series of contractions: a series of three maximal voluntary contractions (MVC) and one sustained contraction (SMVC). After each contraction series, there will be a 2-minute recovery period.

Statistical Analysis. Individual NIRS parameters for MPP subjects will be compared to controls by independent sample t-test or Wilcoxon signed-rank test. To generate a predictive model for MPP diagnosis, we will use Least Angle Shrinkage and Selection Operator (LASSO) to identify candidate predictors from individual NIRS features using ten-fold cross-validation. From potential predictors (i.e., non-zero coefficients), we will select features with standardized shrunken coefficients >0.4 to be used in a multivariable logistic regression model. Only statistically significant model coefficients will be retained to provide a reduced predictive model, whose performance will be evaluated by area under the receiver operating curve (AUROC). AUROC values >0.7 will be demonstrative of an acceptable diagnostic test. We will also report the sensitivity, specificity, and accuracy of the model to quantify anticipated impact.

Outcome: NIRS-based algorithm for the diagnosis of MPP. Impact: The R61 phase will validate vaginal NIRS as an effective, non-invasive, and scalable method to assess pelvic floor muscle fitness, correlating well with current measures of PFM strength and distinguishing the myofascial dysfunction associated with MPP from healthy controls.

Masking: None Allocation: Non-randomized

Being tested
Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy
Keywords
pelvic pain
Medical subject headings
Pelvic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pelvic Floor Muscle Assessment by Near-Infrared SpectroscopyDiagnostic test

    This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations.

Study groups in NCT07181447
Study groupRoleWhat they receive
Control SubjectsWomen age 18 or older without pelvic pain or other genitourinary complaints
Receives: Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy
Myofascial Pelvic Pain SubjectsWomen age 18 or older with pelvic floor muscle pain or tender points
Receives: Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MPP Diagnosis

    Accurate Diagnosis of Myofascial Pelvic Pain

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2025
  2. Study start23 Jan 2025
  3. Primary completion1 Jul 2026
  4. Study completion1 Sep 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07181447
Sponsor's protocol ID
22-0428
Other IDs
R61AT013008-01
Status last verified
Sep 2025
First submitted
11 Sep 2025
Last updated
15 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Once the study is completed, deidentified data will be submitted to a generalist repository that is supported by the BioMedical Informatics Coordinating Committee (BMIC) of the NIH, specifically the Harvard Dataverse open-source research data repository (https://dataverse.org).

Questions about this trial

What is this clinical trial studying?

An observational study of Myofascial Pelvic Pain, run by University of California, Los Angeles at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MPP Diagnosis (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in